Emphasizing the need for clinical guidelines for the treatment of multiple sclerosis (MS), Leslie Fish, PharmD, explains that national guidelines would be helpful when determining the appropriateness of first-line versus second-line therapy.
Dr Fish believes that national guidelines would provide helpful information about treatment effectiveness, and could define which agents should be recommended as second-line therapy based on their side effects.
Gary M. Owens, MD, recognizes that there is no single preferred agent for the treatment of MS and clinicians have fallen into a poor trend as they commonly recommend the most popular options as first-line treatment.
For this reason, there is hesitancy from insurers and clinicians about utilizing newer oral agents for treatment. Dr Owens believes that this issue needs to be addressed, especially as new agents continue to develop.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Forging a Patient-Centric Path to Revolutionize and Redefine Value-Based Care
April 30th 2024Optum Life Sciences and Takeda Pharmaceuticals are partnering on an innovative virtual care pilot program for inflammatory bowel disease meant to both continue the mission of the current value-based health care landscape and raise the bar for personalized care delivery optimization.
Read More
USPSTF Lowers Age for Biennial Mammograms to 40, Citing Early Detection Benefit
April 30th 2024The USPSTF lowered the recommended starting age for mammograms from 50 to 40 years, citing moderate benefits for early detection in this age group. Disparities persist, especially for Black women, highlighting the need for improved access to health care and social support.
Read More